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Abstract
 
Patients with a recently identified subepithelial blistering
disease have IgG anti–laminin 5 autoantibodies. To deter-
mine if such antibodies can be pathogenic in vivo, we devel-
oped and characterized rabbit anti–laminin 5 IgG, and pas-
sively transferred these antibodies to neonatal mice. Immune
rabbit IgG specifically bound human and murine epidermal
basement membranes, immunoblotted and immunoprecipi-
tated all laminin 5 subunits from extracts of human and
murine keratinocytes, and showed no reactivity to other ke-
ratinocyte proteins or epithelial basement membranes that
do not contain laminin 5. Mice (
 
n 
 
5
 
 29) receiving purified
anti–laminin 5 IgG developed, in a dose-related fashion, cir-
culating anti–laminin 5 antibodies, deposits of rabbit IgG
and murine C3 in epidermal basement membranes, and
subepidermal blisters of skin and mucous membranes. No
alterations developed in controls (
 
n 
 
5
 
 14) receiving identi-
cal amounts of normal rabbit IgG. Passive transfer of anti–
laminin 5 (but not control) IgG to neonatal C5- (
 
n 
 
5
 
 3) or
mast cell–deficient (
 
n 
 
5
 
 3) mice produced subepidermal
blisters with the same clinical, histologic, and immuno-
pathologic features as those documented in BALB/c mice.
These studies establish an animal model of a human blister-
ing disease that can be used to define disease mechanisms
and treatment modalities. (
 
J. Clin. Invest. 
 
1996. 98:1509–
1518.) Key words: autoimmunity 
 
•
 
 
 
laminin 
 
•
 
 animal models
 
Introduction
 
Cicatricial pemphigoid is an acquired, autoimmune, subepithe-
lial blistering disease that predominates on mucous mem-
branes. Recent studies have shown that 
 
z
 
 5% of patients with
well characterized cicatricial pemphigoid have IgG anti–base-
ment membrane (BM)
 
1
 
 autoantibodies directed against lami-
nin 5 (also called laminin isoform 5, nicein, epiligrin, and kali-
nin) (1–7). Laminin 5 (
 
a
 
3
 
b
 
3
 
g
 
2) is a heterotrimeric adhesion
molecule that is associated with anchoring filaments in the
lamina lucida of human epidermal BM (8–10). These filaments
comprise part of an adhesion complex that anchors basal kera-
tinocytes to epidermal BM. Like many other constituents of
epidermal BM, laminin 5 is produced by human keratinocytes
(HK) (8–11). In vitro, HK deposit laminin 5 in their extracellu-
lar matrix (ECM) where this protein serves as the major inte-
grin ligand for these cells (8, 9, 12). Interestingly, certain mono-
clonal anti–laminin 5 antibodies have been shown to impair
HK adhesion to ECM in vitro (9). These experimental findings
have raised the hypothesis that anti–laminin 5 autoantibodies
in patients with cicatricial pemphigoid may impair the adhe-
sion of basal keratinocytes to epidermal BM in a similar man-
ner and hence are pathogenic in vivo. To address this hypothe-
sis, we immunized rabbits with laminin 5 purified from the
ECM of HK, purified and characterized the resulting rabbit
anti–laminin 5 IgG, and then passively transferred the latter
into neonatal mice. Studies using this animal model of disease
demonstrate that anti–laminin 5 (but not normal, control) IgG
induces subepithelial blisters in newborn mice at doses as low
as 1 mg/g body wt. Moreover, these studies demonstrate that
such lesions develop in newborn mice independent of the acti-
vation of terminal complement components or the degranula-
tion of dermal mast cells. These studies establish an animal
model of a human blistering disorder that can be used to inves-
tigate disease pathomechanisms and experimental therapies.
 
Methods
 
Reagents
 
FITC-conjugated goat anti–rabbit IgG (Tago, Inc., Burlingame, CA),
FITC-conjugated goat anti–rabbit IgM (Cappel Laboratories, West
Chester, PA), FITC-conjugated goat anti–mouse C3 (Cappel Labora-
tories), FITC-conjugated goat anti–mouse IgM (Cappel Laborato-
ries), rabbit anti–laminin 5 antiserum (a control reagent generously
provided by Dr. Peter Marinkovich, Stanford University, Stanford,
CA, and Dr. Robert Burgeson, Harvard Medical School, Cambridge,
MA), normal rabbit serum (GIBCO BRL, Grand Island, NY), serum
from a reference patient with antiepiligrin cicatricial pemphigoid who
has IgG anti–BM autoantibodies directed against laminin 5, and nor-
mal human serum were used as described below (1–3). Protein A–
bearing formalin-fixed staphylococci (Pansorbin) were obtained from
Calbiochem-Behring Corp. (San Diego, CA). Collagen types I, III, V,
and VII (Calbiochem-Behring Corp.), human plasma fibronectin,
laminins 1 (
 
a
 
1
 
b
 
1
 
g
 
1) and 2 (
 
a
 
2
 
b
 
1
 
g
 
1) (the latter formerly called
merosin), and type IV collagen (GIBCO BRL), and human as well as
bovine serum albumin (Sigma Chemical Co., St. Louis, MO) were
used as described below.
 
Address correspondence to Kim B. Yancey, Dermatology Branch,
NCI, Building 10, Room 12N238, National Institutes of Health, 10
Center Drive MSC 1908, Bethesda, MD 20892-1908. Phone: 301-402-
1863; FAX: 301-496-5370.
 
Received for publication 27 March 1996 and accepted in revised
form 31 July 1996.
 
1. 
 
Abbreviations used in this paper:
 
 BM, basement membrane; ECM,
extracellular matrix; HK, human keratinocyte; IF, immunofluores-
cence.
 
 
1510
 
Lazarova et al.
 
Cell cultures
 
HK were derived from newborn human foreskins and cultured in Ke-
ratinocyte SFM (GIBCO BRL) (13). The skin of neonatal BALB/c
mice was excised and treated with 0.25% trypsin in Hank’s balanced
salt solution containing Ca
 
11
 
 and 1 mM Hepes at 4
 
8
 
C for 16 h. Sheets
of murine epidermal cells were recovered, disaggregated, and cul-
tured in Keratinocyte SFM.
 
Laminin 5
 
Laminin 5 was isolated from the ECM of cultured HK as described
previously (3, 8). In brief, confluent cultures of HK were sequentially
extracted with 1% Triton X-100 in PBS, 2 M urea in 1 M NaCl, and
8 M urea to yield culture dishes coated with laminin 5. Urea-insoluble
proteins were detached from the surface of culture dishes with a dis-
posable cell scrapper (Costar Corp., Cambridge, MA) and suspended
in 0.5% (wt/vol) SDS; all extraction buffers contained 1 mM phenyl-
methylsulfonyl fluoride and 2 mM 
 
N
 
-ethylmaleimide. Laminin 5 de-
rived from HK ECM was dialyzed against 0.1% SDS in Tris-buffered
saline at 4
 
8
 
C, concentrated by solvent recovery (Sephadex G-75;
Pharmacia Fine Chemicals, Uppsala, Sweden), and stored at 
 
2
 
70
 
8
 
C.
 
Immunization of rabbits
 
Sera from 10 New Zealand White rabbits were tested for evidence of
circulating IgG reactive with human epidermis or epidermal BM by
indirect immunofluorescence (IF) microscopy (14). Preimmune sera
were collected from four rabbits showing the lowest background re-
activity to human skin, and these subjects were immunized subcuta-
neously with purified laminin 5 (100 
 
m
 
g/ml) suspended in Freund’s
complete adjuvant. 14 d later, each subject was boosted once with the
same preparation of laminin 5 (100 
 
m
 
g/ml) suspended in incomplete
Freund’s adjuvant. Immune sera were obtained at regular intervals,
characterized separately, and used as individual reagents in the pas-
sive transfer studies described below.
 
Characterization of rabbit anti–laminin 5 antibodies
 
Indirect IF microscopy.
 
Serial dilutions of immune (and preimmune,
control) rabbit sera were tested for IgG reactive with intact human
and neonatal murine skin as well as 1 M NaCl split human skin by in-
direct IF microscopy (14). The same samples were also tested for IgG
reactive with laminin 5 in the ECM of HK by indirect IF microscopy
as described previously (1, 2). The tissue distribution of the reactivity
of anti–laminin 5 antisera was determined in indirect IF microscopy
studies of tissues from humans (skin, vagina, colon, kidney, gall blad-
der, and synovium), BALB/c mice (skin, oral mucosa, conjunctiva,
cornea, tongue, and kidney), and New Zealand White rabbits (skin).
 
Complement fixation.
 
Immune (and preimmune, control) rabbit
sera were tested for their ability to elicit deposition of human C3 in
normal human epidermal BM using a previously described indirect IF
microscopy complement fixation technique (15, 16).
 
Immunoblot.
 
Immune (and preimmune, control) rabbit sera
were characterized for their pattern of IgG reactivity against all pro-
teins extracted from HKs and HK ECM by immunoblotting. In these
experiments, cultured HK were extracted with Tris-buffered saline
containing 1% SDS, 5% 
 
b
 
-mercaptoethanol, 2 mM EDTA, 2 mM
phenylmethylsulfonyl fluoride, and 5 mM each of leupeptin, antipain,
chymostatin, and pepstatin A; HK ECM was isolated as described
above. Samples of HK extracts or ECM were reduced and applied to
6% SDS–polyacrylamide minigels (Novex, San Diego, CA), trans-
ferred to nitrocellulose paper (Bio-Rad Laboratories, Hercules, CA)
by electrophoresis, and immunoblotted with immune and preimmune
rabbit sera (3, 17, 18). Alkaline phosphatase–conjugated goat anti–
rabbit IgG (1:1,000) was used as the second-step antibody in these
studies; immunoblots were developed for 3 min (alkaline phos-
phatase–conjugate substrate kit; Bio-Rad Laboratories), and then
washed extensively with Tris-buffered saline. Reference rabbit anti–
laminin 5 antiserum and normal rabbit serum were used as additional
controls to specifically identify all laminin 5 subunits (i.e., unproc-
essed and/or processed 
 
a
 
, 
 
b
 
, and 
 
g
 
 subunits) in these samples. In re-
lated experiments, immune (and preimmune, control) rabbit sera
were immunoblotted against all proteins extracted from subconfluent
monolayer cultures of BALB/c epidermal cells. Murine epidermal
cells were extracted and analyzed in the same manner as HK with the
exception that chemiluminescence (ECL
 
TM
 
; Amersham Corp., Life
Sciences, Little Chalfont, UK) was used to develop the immunoblots;
again, the reference anti–laminin 5 antiserum served as the positive
control for these experiments.
To further characterize the reactivity of anti–laminin 5 IgG, im-
mune (and preimmune, control) sera were tested against collagen
types I, III, IV, V, and VII, laminins 1 and 2, human plasma fibronec-
tin, and human as well as bovine serum albumin by dot immunoblot.
 
Immunoprecipitation.
 
Subconfluent monolayers of HKs were
metabolically radiolabeled with 
 
35
 
S-methionine (50 
 
m
 
Ci/ml; specific
activity 
 
z
 
 1,100 Ci/mmol; New England Nuclear, Boston, MA) in me-
thionine-free media. Radiolabeled HK extracts and culture medium
were processed as described previously and studied by immunopre-
cipitation using immune and preimmune rabbit sera, reference rabbit
anti–laminin 5 antiserum, serum from a reference patient with anti–
epiligrin cicatricial pemphigoid, and normal human serum (19, 20).
Using the same techniques, monolayer cultures of BALB/c epidermal
cells were metabolically radiolabeled, extracted, and studied in im-
munoprecipitation experiments using anti–laminin 5, preimmune,
and reference positive control rabbit sera. Immunoprecipitation sam-
ples were studied by gradient SDS–PAGE and fluorography.
 
Purification of rabbit IgG
 
Immune (and normal, control) rabbit IgG was purified by chromatog-
raphy on Affi-Gel Blue Gel (Bio-Rad Laboratories), concentrated by
ultrafiltration (Centricon 30; Amicon Corp., Danvers, MA), and ana-
lyzed on Coomassie blue–stained SDS–polyacrylamide gels contain-
ing standards of known concentration. These studies demonstrated
that the immune and normal rabbit IgG preparations used in these
studies were purified to homogeneity. Final IgG concentrations were
determined by OD
 
280
 
 using an extinction coefficient (1%, 1 cm) of
13.6.
 
Neonatal mice
 
Neonatal BALB/c and DBA/2NCr mice were obtained from the Na-
tional Institutes of Health animal care facility (Frederick Cancer Re-
search and Development Center, Frederick, MD). DBA/2NCr mice
are known to be C5-deficient on the basis of being homozygous for
the Hc
 
o
 
 allele. Female C57Bl/6J (W
 
v
 
/
 
1
 
) and male W
 
b
 
ReJ (W/
 
1
 
) mice
were obtained from The Jackson Laboratories (Bar Harbor, ME) and
bred to produce W/W
 
v
 
 (mast cell–deficient) neonates; littermates
served as controls for these subjects. In passive transfer studies, W/W
 
v
 
neonates and their littermates were studied in a completely blinded
manner since the distinguishing features of the former are first mani-
fest clinically at 2–3 d of age. For confirmation of phenotype, the rela-
tive number of dermal mast cells in these mice was determined in
light microscopy studies of skin sections stained with toluidine blue
and Giemsa.
 
Passive transfer studies
 
Neonatal BALB/c, DBA/2NCr, W/W
 
v
 
, and littermate control mice,
24–36 h old with a body weight of 1.3–1.8 g were used in these studies.
Purified anti–laminin 5 (or normal, control) rabbit IgG was adminis-
tered subcutaneously or intraperitoneally to neonatal mice as previ-
ously described (21–23); the majority of these animals received IgG
via subcutaneous injection. IgG doses ranged from 0.01 to 10 mg/g
body wt/d for 2–4 d. To avoid administration of excessive fluid vol-
umes, IgG concentrations as high as 100 mg/ml were used; the maxi-
mal injection volume for any subject was 100 
 
m
 
l.
 
Evaluation of neonatal mice
 
Mice were examined daily for determination of their general well be-
ing as well as evidence of cutaneous or mucosal alterations (specifi-
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cally, erythema, edema, blisters, erosions, or crusts). At 3, 6, 12, 24,
and 48 h, as well as other selected time points after the passive trans-
fer of IgG, animals were killed and pieces of skin as well as oral and
nasal mucosa were fixed in 10% buffered formalin, stained with he-
matoxylin and eosin, and studied by light microscopy. Samples of kid-
ney and heart were also obtained from experimental and control mice
and processed for light microscopy studies. Direct IF and immu-
nogold electron microscopy of skin from experimental and control
subjects was performed as described previously (14, 24). The former
employed reagents directed against rabbit IgG, rabbit IgM (control),
murine C3, and murine IgM (control), while the latter used 10-nm
gold-labeled goat anti–rabbit conjugate (Jannsen Pharmaceuticals,
Piscataway, NJ). Sera were obtained from mice at the time of killing
and studied by indirect IF microscopy to detect the presence (and ti-
ters) of circulating rabbit IgG directed against epidermal BM in 1 M
NaCl split normal human skin. All passive transfer experiments in-
cluded mice that received purified normal rabbit IgG (i.e., controls);
these subjects were studied in the same manner as mice receiving
anti–laminin 5 IgG.
 
Results
 
Laminin 5
 
SDS–polyacrylamide gel electrophoresis and immunoblot stud-
ies using the previously described reference anti–laminin 5 an-
tiserum demonstrated that the laminin 5 purified from HK
ECM was recovered as a complex of five disulfide-linked
Figure 1. IgG in immune rabbit serum 
specifically binds laminin 5 in HK ECM 
and cell extracts. (A) By immunofluores-
cence microscopy, laminin 5 between 
and beside colonies of subconfluent and 
nonpermeabilized cultured HKs is rec-
ognized by IgG in immune (left) but not 
preimmune (right) rabbit sera. (B) IgG 
in immune (lane 3) and reference posi-
tive control (lane 1) rabbit sera specifi-
cally immunoblot the unprocessed and 
processed a subunits (200 and 165 kDs, 
respectively), the b subunit (140 kD), 
and the unprocessed and processed g 
subunits (155 and 105 kDs, respectively) 
of laminin 5 in total protein extracts of 
cultured HK. IgG in normal (lane 2) and 
preimmune (lane 4) rabbit sera do not 
immunoblot any HK proteins on these 
reduced 6% SDS–polyacrylamide gels. 
The markers in the right margin indicate 
the Mr 3 10
23. (C) In studies of metabol-
ically radiolabeled human keratinocyte 
media, IgG in immune (lane 2) and ref-
erence positive control (lane 1) rabbit 
sera specifically immunoprecipitate a set 
of disulfide-linked polypeptides of 165, 
145, 140, and 100 kDs that comigrate on 
a reduced 4–12% gradient SDS–poly-
acrylamide gel. Preimmune rabbit serum 
(lane 3, control) shows no reactivity to 
any HK proteins in these immunoprecip-
itation studies. The markers in the right 
margin indicate the Mr 3 10
23. (Note: 
the minor variance in the calculated mo-
lecular weights of the unprocessed and 
processed g subunits of laminin 5 in B 
and C is related to the differences in the 
acrylamide content of these respective 
gels.)
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polypeptides corresponding to the unprocessed and processed
 
a
 
 subunits (200 and 165 kDs, respectively), the 140 kD 
 
b
 
 sub-
unit, and the unprocessed and processed 
 
g
 
 subunits (155 and
105 kDs, respectively). Laminin 5 was free of contaminating
proteins or degradation fragments.
 
Characterization of rabbit anti–laminin 5 IgG
Indirect IF microscopy.
 
Circulating IgG from immune (but
not preimmune or normal) rabbits bound epidermal BM in in-
tact human and neonatal murine skin at a titer of 10,240 and
the dermal side of 1 M NaCl split human skin at a titer of
20,480. After purification, IgG from immune rabbits bound the
latter IF test substrate with a titer of 40,960, while purified nor-
mal rabbit IgG remained free of reactivity. IgG in immune
(but not preimmune) sera also bound laminin 5 in HK ECM
by indirect IF microscopy (Fig. 1 
 
A
 
). Anti–laminin 5 antisera
bound epithelial BMs in human epidermis, vagina, and colon
as well as murine epidermis, oral mucosa, conjunctiva, and cor-
nea. Anti–laminin 5 antisera did not bind BMs in human or
murine blood vessels (a tissue site of laminin 1 [
 
a
 
1
 
b
 
1
 
g
 
1]),
nerves (synapses containing laminin 3 [
 
a
 
1
 
b
 
2
 
g
 
1), or kidney (a
site of laminins 1 and 3), BMs in human gall bladder or syno-
vium, the basal lamina of striated muscle in murine tongue (a
site of laminin 2 [
 
a
 
2
 
b
 
1
 
g
 
1]), or any BMs in rabbit skin.
 
Complement fixation.
 
Sera from immune (but not preim-
mune or normal) rabbits activated human complement in vitro
and elicited deposition of C3 in human epidermal BM at the
site corresponding to the localization of anti–laminin 5 IgG
(data not shown).
 
Immunoblot.
 
IgG in immune and positive control rabbit
sera (but not preimmune or normal rabbit sera) specifically iden-
tified polypeptides that correspond to the previously described
unprocessed and/or processed 
 
a
 
, 
 
b
 
, and 
 
g
 
 subunits of laminin 5
in total protein extracts of cultured HKs and BALB/c epider-
mal cells (Figs. 1 
 
B
 
 and 2, respectively) as well as HK ECM
(data not shown). No other proteins in extracts of HKs,
BALB/c epidermal cells, or HK ECM were recognized by IgG
from rabbits immunized with laminin 5.
In direct comparative immunoblot studies, anti–laminin 5
(but not preimmune, control) sera specifically bound laminin 5
in extracts of HK ECM, but showed no reactivity to collagen
types I, III, IV, V, or VII, laminins 1 or 2, human plasma fi-
bronectin, or human as well as bovine serum albumin.
 
Immunoprecipitation. 
 
Further evidence of the specificity
of the anti–laminin 5 IgG in immune sera of these four rabbits
Figure 2. IgG in immune rabbit serum spe-
cifically binds laminin 5 in total protein ex-
tracts of cultured BALB/c epidermal cells. 
IgG in immune (lane 1) but not preimmune 
(lane 2) rabbit sera specifically immunoblots 
the processed a subunit (165 kD), the b sub-
unit (140 kD), and the unprocessed and pro-
cessed g subunits (150 and 105 kDs, respec-
tively) in total protein extracts of cultured 
BALB/c epidermal cells. The same proteins 
were identified by the reference positive 
control anti–laminin 5 antiserum, but re-
quired a longer exposure of the chemilumi-
nescent substrate (data not shown). The 
markers in the left margin indicate the
Mr 3 10
23.
Figure 3. Anti–laminin 5 IgG specifically induces subepidermal blis-
ters and peeling in vivo. (A) A large, tense blister is evident on the ab-
domen of a neonatal BALB/c mouse 24 h after passive transfer of 10 
mg/g body wt of purified anti–laminin 5 IgG. A control subject that re-
ceived an identical dose of normal rabbit IgG showed no clinical or 
microscopic evidence of epidermal separation. (B) Full-thickness 
peeling of epidermis away from the margin of incised skin is apparent 
in a BALB/c mouse killed 24 h after passive transfer of 10 mg/g body 
wt of anti–laminin 5 IgG. (C) A small blister is present on the plantar 
surface of an experimental subject 24 h after the passive transfer of 10 
mg/g body wt of anti–laminin 5 IgG. Light microscopy studies con-
firmed that this lesion signified a subepidermal blister (see Fig. 3 C).
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was demonstrated in immunoprecipitation studies of metaboli-
cally radiolabeled extracts of HK and murine epidermal cells
as well as the conditioned media of cultured HKs. In these
studies, immune (but not preimmune) rabbit sera identified
disulfide-linked polypeptides that comigrated in SDS–poly-
acrylamide gels with the same polypeptides immunoprecipi-
tated by reference laminin 5 antiserum (Fig. 1 C) as well as se-
rum from a patient with anti–epiligrin cicatricial pemphigoid
(data not shown).
Passive transfer studies
Clinical findings. Neonatal BALB/c mice (24–36 h of age)
were injected subcutaneously (along the back) or intraperito-
neally with purified rabbit anti–laminin 5 (or normal rabbit)
IgG daily for 2–4 d. Within 24–48 h, mice that received total
doses of anti–laminin 5 IgG exceeding 5 mg/g body wt (n 5 17)
developed tense blisters on their abdomen, feet, and/or ears
(Fig. 3, A and C). The number and size of blisters in these mice
developed in a dose-related manner and were often accompa-
nied by faint, localized erythema (Table I). Blisters were not
localized to injection sites, but rather predominated in areas
exposed to friction or trauma. The same pattern of lesions de-
veloped in mice that received anti–laminin 5 IgG via subcuta-
neous or intraperitoneal injections. While these mice were not
frankly “Nikolsky’s positive” (i.e., subject to epidermal loss
secondary to lateral mechanical pressure), incision of their
skin within 1–4 d of anti–laminin 5 administration created epi-
dermal detachment and peeling that allowed sheets of epider-
mis to be lifted away from the underlying nonadherent dermis
(Fig. 3 B).
Time course studies after passive transfer of 5 mg/g body
wt of anti–laminin 5 IgG to neonatal BALB/c mice indicated
that while no clinical or histologic alterations were evident
within 3 h microscopic subepidermal blisters were detectable
at 6 h (see below), epidermal peeling developed within 12 h,
and frank, tense blisters were present within 24–48 h after the
administration of specific immunoglobulin. Interestingly, BALB/c
mice that received . 5 mg/g body wt of anti–laminin 5 IgG
continued to develop new blisters as late as 8 d after passive
transfer of antibody. Blisters at these and earlier time points
were replaced by erosions and/or crusts that were followed
within a few days by reepithelization. Subsequent alterations
documented in eight mice followed daily for as long as 12 wk
after passive transfer of these doses of anti–laminin 5 IgG con-
sisted only of coat abnormalities and diminished growth (early
findings that proved to be relatively minor and transient).
In BALB/c mice that received total doses of 1–2.5 mg/g
body wt of anti–laminin 5 IgG (n 5 4), clinical findings were
limited to peeling of epidermis after skin incision (Table I).
There was no evidence of clinical lesions or peeling in mice
that received , 1 mg/g body wt of anti–laminin 5 IgG (n 5 8)
or in any BALB/c mice that received 2–20 mg/g body wt of
normal rabbit IgG (controls, n 5 14).
Passive transfer of 5 or 10 mg/g body wt of anti–laminin 5
IgG also induced blisters, erosions, and peeling in newborn
DBA/2NCr (C5-deficient) mice (n 5 3) as well as W/Wv (mast
cell–deficient) mice (n 5 3) and W/Wv littermate controls (n 5
8) (Table I). Again, no alterations were induced in neonatal
DBA/2NCr (n 5 2), W/Wv (n 5 2), or W/Wv littermates (n 5
5) that received equivalent doses of purified normal rabbit IgG.
Table I. Passive Transfer Studies
IgG* Dose‡
Findings§
Direct IFi Indirect IF¶ NumberClinical Microscopic
mg/gm
BALB/c mice
R/L5 20 Blisters, peeling Subepidermal blister IgG, C3 40,960 2
R/L5 5–10 Vesicles, peeling Subepidermal blister IgG, C3 20,480–40,960 15
R/L5 1–2.5 Peeling Subepidermal blister IgG, C3 5,120 4
R/L5 0.01–0.20 Normal Normal IgG, C3 20–320 8
R IgG 2–20 Normal Normal Negative Negative 14
DBA/2NCr mice
R/L5 10 Vesicles, peeling Subepidermal blister IgG, C3 40,960 3
R IgG 10 Normal Normal Negative Negative 2
W/Wv mice
R/L5 5 Vesicles, peeling Subepidermal blister IgG, C3 20,480 3
R IgG 5 Normal Normal Negative Negative 2
W/Wv littermates
R/L5 5 Vesicles, peeling Subepidermal blister IgG, C3 20,480 8
R IgG 5 Normal Normal Negative Negative 5
Total 5 66
*Type of purified IgG passively transferred to neonatal mice; R/L5 signifies purified rabbit anti–laminin 5 IgG, R IgG signifies purified normal rabbit
IgG. ‡Total doses of purified IgG passively transferred to neonatal mice in divided doses over 2–4 d. §Summary of major clinical and light microscopy
findings in experimental and control mice (see text for details). iDirect IF microscopy results refer to the immunoreactants identified in the epidermal
BMs of mice receiving IgG by passive transfer. ¶Indirect IF microscopy results refer to the titer of circulating rabbit IgG directed against the dermal
side of 1 M NaCl split normal human skin.
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Light microscopy. Light microscopy studies of flank and
abdominal skin obtained from neonatal BALB/c mice 1–2 d
after subcutaneous or intraperitoneal injection of anti–laminin
5 IgG (1–20 mg/g body wt; n 5 21) revealed broad areas of
subepidermal blister formation (Fig. 4 A). Such lesions were
present even in what was clinically considered to be intact skin
(epidermal separation and peeling being a common develop-
ment during necroscopy). Similar lesions were also evident in
histologic studies of plantar skin (Fig. 4 C) as well as oral and
nasal epithelia. As noted earlier, microscopic subepidermal
blisters were present in BALB/c neonates as early as 6 h after
passive transfer of 5 mg/g body wt of anti–laminin 5 IgG. Sub-
epidermal blisters were free of leukocytic infiltrates, dermal
edema, or necrotic keratinocytes (Figs. 4, A and C). Moreover,
these studies found a correlation between the amount of pas-
sively transferred IgG and the extent of subepidermal blister
formation in subjects receiving 1–20 mg/g body wt of anti–
laminin 5 IgG. Light microscopy studies of skin from experi-
mental mice that received , 1 mg/g body wt of anti–laminin 5
IgG (n 5 8) or control subjects injected with 2–20 mg/g body
wt of normal rabbit IgG (n 5 14) showed normal intact murine
skin devoid of any infiltrates or other histopathological alter-
ations (Fig. 4, B and D). There was no evidence of vasculitis in
skin biopsies from any experimental or control BALB/c mice.
In addition, light microscopy studies of kidneys and hearts
from representative experimental and control mice were iden-
tical and found no evidence of hemorrhage, vasculitis, or tissue
alteration.
Light microscopy studies of skin from neonatal DBA/2NCr
(n 5 3), W/Wv (n 5 3), and W/Wv littermate (n 5 8) mice 1–2 d
after passive transfer of 5–10 mg/g body wt of anti–laminin 5
IgG also revealed noninflammatory subepidermal blisters free
of leukocytic infiltrates, dermal edema, necrotic keratinocytes,
or vasculitis. Light microscopy studies of DBA/2NCr (n 5 2),
W/Wv (n 5 2), and W/Wv littermates (n 5 5) that received
equivalent total doses of normal rabbit IgG (controls) revealed
normal intact murine skin.
IF microscopy. Direct IF microscopy of skin from all neo-
natal BALB/c mice that received anti–laminin 5 IgG revealed
continuous deposits of rabbit IgG in epidermal BMs (Fig. 4 E)
(Table I). The relative intensity of these immunoreactants di-
rectly correlated with the dose of passively transferred anti–
laminin 5 IgG. All mice that received total doses of anti–laminin
5 IgG exceeding 1 mg/g body wt had very bright in situ depos-
its of rabbit IgG in their epidermal BMs; in blistered skin, such
deposits were almost exclusively localized to the dermal side of
the sample. Sequential studies of BALB/c mice that received 5
mg/g body wt of anti–laminin 5 IgG (n 5 6) found that in situ
deposits of IgG in epidermal BM persisted for as long as 7 wk
(the longest time point examined). In addition to deposits of
rabbit IgG, continuous deposits of murine C3 were also found
in the epidermal BMs of all neonatal BALB/c mice that re-
ceived anti–laminin 5 IgG (Fig. 4 G). Direct IF microscopy of
skin from neonatal DBA/2NCr, W/Wv, and W/Wv littermates
that received anti–laminin 5 IgG also revealed continuous de-
posits of rabbit IgG and murine C3 in epidermal BMs. There
were no deposits of rabbit IgG or murine C3 in the epidermal
BMs of any mice that received normal rabbit IgG (Fig. 4, F
and H).
Indirect IF microscopy studies of sera from neonatal
BALB/c, DBA/2, W/Wv, and W/Wv littermates 1–2 d after pas-
sive transfer of anti–laminin 5 IgG identified circulating rabbit
IgG that bound the dermal side 1 M NaCl split human skin. Ti-
ters of circulating rabbit anti–BM IgG in these mice correlated
with the dose of passively transferred antibody and ranged
from 5,120 to 40,960 in mice receiving total doses of 1–20 mg/g
body wt of anti–laminin 5 IgG (Table I). Sequential studies of
sera from BALB/c mice that received 5 mg/g body wt of anti–
laminin 5 IgG found that circulating anti–BM antibodies were
present in their circulation for as long as 4 wk (the longest time
point examined). All indirect IF microscopy studies of sera
from mice that received normal rabbit IgG were negative.
Direct immunogold electron microscopy. Direct immunogold
electron microscopy studies of intact skin from a representa-
tive BALB/c mouse that received 5 mg/g body wt of anti–lami-
nin 5 IgG localized deposits of rabbit IgG to the interface of
the lamina lucida and the lamina densa (Fig. 5 A). Some de-
posits of IgG were also localized to the adjacent lamina densa
itself. There were no deposits of gold beads in the intact skin of
a representative BALB/c mouse that received equivalent total
doses of normal rabbit IgG (Fig. 5 B).
Discussion
The stratified squamous epithelium of human epidermis is de-
rived from proliferating basal keratinocytes that are attached
to epidermal BM. Adhesion of basal keratinocytes to epider-
mal BM is critical for epithelial polarization, differentiation,
morphogenesis, and wound healing. Laminin 5 is a recently
identified laminin isoform that has been localized to the lam-
ina lucida of epidermal BM where it is associated with anchor-
ing filaments, ultrastructural elements that link basal kerati-
nocytes to epidermal BM in vivo. In vitro, laminin 5 is one of
the major components of HK-derived ECM (8, 9). Laminin 5
promotes the adhesion of HK to ECM by serving as the pre-
ferred ligand for integrin a3b1 in plasma membranes and focal
adhesions, and colocalizing with integrin a6b4 in hemidesmo-
some-like stable anchoring complexes (8, 12). Interestingly,
monoclonal antibodies directed against laminin 5 have been
shown to impair the adhesion of HKs to their ECM (experi-
mental findings that attest to the important role that this pro-
tein plays in HK adhesion in vitro) (9). Relatedly, recent stud-
ies have identified abnormalities of laminin 5 in vivo in
patients with inherited and autoimmune subepidermal blister-
ing diseases (10). For example, it has been shown that laminin
Figure 4. Anti–laminin 5 IgG passively transferred to neonatal 
BALB/c mice binds epidermal BMs, fixes complement, and induces 
noninflammatory subepidermal blisters in vivo. Light and immuno-
fluorescence microscopy studies of skin from neonatal BALB/c mice 
24 h after administration of 10 mg/g body wt of purified anti–laminin 
5 IgG (A, C, E, and G) or normal, control IgG (B, D, F, and H). He-
matoxylin- and eosin-stained sections of flank and plantar skin (A 
and C, respectively) from experimental subjects show separation of 
epidermis from epidermal BM and the resulting subepidermal blis-
ters; lesions have developed in the absence of leukocytic infiltrates, 
dermal edema, or necrotic keratinocytes. Immunofluorescence mi-
croscopy studies of flank skin from an experimental subject show in 
situ deposits of rabbit IgG (E) and murine C3 (G) in BMs of the epi-
dermis and hair follicles. In contrast, the flank (B) and plantar (D) 
skin of mice that received equivalent doses of purified normal rabbit 
IgG is intact and free of in situ deposits of rabbit IgG (F) and murine 
C3 (H) in epidermal BMs.
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5 is absent or diminished in the epidermal BM of patients with
Herlitz’s junctional epidermolysis bullosa, a potentially lethal
inherited blistering disease (25–27). Moreover, mutations in
genes encoding laminin 5 subunits have recently been identi-
fied in these patients (28–30). Another indication of the key
role that this protein plays in epidermal adhesion in vivo was
provided by studies showing that patients with one form of cic-
atricial pemphigoid, an acquired subepithelial blistering dis-
ease of mucous membranes and skin, have IgG anti–BM au-
toantibodies directed against laminin 5 (1–5). Thus, acquired
and inherited abnormalities in laminin 5 have been directly
linked to diseases characterized by separation of epidermis
from epidermal BM in human skin.
The ability of monoclonal anti–laminin 5 antibodies to im-
pair HK adhesion in vitro raised the possibility that anti–lami-
nin 5 autoantibodies in patients with cicatricial pemphigoid
may be pathogenic in vivo. To investigate this hypothesis, we
immunized rabbits with laminin 5 purified from the ECM of
HK, purified and characterized the resulting rabbit anti–lami-
nin 5 IgG, and then passively transferred the latter into neona-
tal mice. Studies using this animal model of disease demon-
strate that anti–laminin 5 (but not normal) IgG induces
subepithelial blisters of skin and mucous membranes that are
noninflammatory, form independent of the activation of termi-
nal complement components or the degranulation of dermal
mast cells, and continue to develop as long as 8 d after the ad-
ministration of antibody. Both intraperitoneal and intradermal
administration of anti–laminin 5 IgG produced subepidermal
blisters in this model. Interestingly, intradermal injections of
anti–laminin 5 IgG did not induce localized inflammatory reac-
tions at injection sites, but rather produced noninflammatory
blisters that predominated elsewhere (largely at sites of fric-
tion or trauma). The anti–laminin 5 IgG employed in these
studies bound all subunits of human and murine laminin 5,
showed a profile of tissue reactivity that is identical to the
known distribution of laminin 5 in vivo, and did not react with
other matrix proteins present in epidermal or other epithelial
BMs. Correspondingly, the tissue specificity of the injury pro-
duced in this animal model (i.e., the induction of subepithelial
blisters in epidermal, oral, and nasal epithelia as well as the ab-
sence of alterations at sites devoid of laminin 5) further attests
to the specificity of the anti–laminin 5 IgG used in these pas-
sive transfer studies.
The experimental approach used in these studies is analo-
gous to the recently developed passive transfer animal model
of bullous pemphigoid (22, 31). Both of these models provide
important insights into the pathophysiology of human blister-
ing diseases despite the fact that passive transfer of human IgG
autoantibodies directed against bullous pemphigoid antigens
or laminin 5 do not cause blisters in mice. As previously re-
ported, human anti–laminin 5 autoantibodies do not bind mu-
rine epidermal BM in vitro (32, 33) or after passive transfer to
mice in vivo (Lazarova and Yancey, unpublished observations).
Such findings are not unexpected since several murine mono-
clonal anti–human laminin 5 antibodies do not bind the epi-
dermal BMs of nonprimates. Our passive transfer studies used
extensively characterized polyclonal anti–laminin 5 IgG directed
against epitopes present on all subunits of human and murine
laminin 5 (including the a subunit of the former, which is tar-
geted by IgG autoantibodies from patients with this form of
cicatricial pemphigoid). In contrast, the recently described pas-
sive transfer model of bullous pemphigoid required the use of
rabbit IgG specifically directed against the murine homologue
of the immunodominant epitope of human bullous pemphi-
goid antigen 2 (22, 31).
Passive transfer of anti–laminin 5 IgG to neonatal mice in-
duced microscopic subepidermal blisters within 6 h, peeling of
epidermis at 12 h, and frank, tense blisters by 24 h. Though
subepidermal blisters continued to develop in neonates for as
long as 8 d after passive transfer of . 5 mg/g body wt of anti-
laminin 5 IgG, none of these animals developed generalized
disease, multiorgan failure, or vasculitis. Anti–laminin 5 IgG
induced subepithelial blisters in vivo in a dose-dependent man-
ner and as little as 1 mg/g body wt of anti–laminin 5 IgG
caused separation of murine epidermis. While the doses of
anti-laminin 5 IgG administered in these studies are compara-
ble to those used in passive transfer models of other human
blistering diseases, there are several notable differences be-
tween our model and other previously described experimental
systems (21–23). For example, in the passive transfer model of
pemphigus vulgaris, blisters develop in neonatal mice within
24 h; development of subsequent lesions requires another in-
jection of pathogenic antibodies. In the recently established
murine model of bullous pemphigoid (22, 31), specific IgG
elicits subepidermal blisters in a complement-dependent man-
ner; lesions fail to develop when pathogenic antibodies are
Figure 5. In situ deposits of 
rabbit anti–laminin 5 IgG 
in murine epidermal BM 
are specifically localized to 
the lamina lucida–lamina 
densa interface and the un-
derlying lamina densa. (A) 
Direct immunogold elec-
tron microscopy of skin 
from a BALB/c mouse that 
received 5 mg/g body wt of 
anti–laminin 5 IgG shows 
specific binding of gold 
particles to the lamina lu-
cida–lamina densa interface and the underlying lamina densa. There is no specific binding of gold particles to the cytoplasm, hemidesmosomes, 
or plasma membranes of overlying basal keratinocytes or to sites in the sublamina densa region. (B) Direct immunogold electron microscopy of 
skin from a BALB/c mouse that received 5 mg/g body wt of normal rabbit IgG shows no specific binding of gold particles to any aspect of basal 
keratinocytes, epidermal BM, or the sublamina densa region.
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passively transferred to C5-deficient or complement-depleted
mice. Finally, passive transfer of high doses of purified IgG
from a patient with severe epidermolysis bullosa acquisita has
been shown to produce alterations in neonatal BALB/c mice
that mimic some aspects of this disease (i.e., deposits of immu-
noreactants in epidermal BM, granulocyte-rich infiltrates in
dermal papillae, and pronounced dermal edema), yet failed to
produce clinical or microscopic subepidermal blisters in vivo
(23). All of these experimental findings differ significantly
from those documented in our passive transfer studies and fur-
ther suggest that anti–laminin 5 IgG produces separation of
epidermis from epidermal BM in vivo by a specific rather than
an inflammatory and potentially nonspecific reaction. More-
over, these experimental findings are in many ways compara-
ble to clinical findings in patients with cicatricial pemphigoid
(specifically, the minimal inflammation present in their mu-
cosal lesions, the cell-poor infiltrate observed in light micros-
copy studies of their lesional tissue, and their occasional poor
response to treatment with systemic glucocorticosteroids).
Induction of blisters in this animal model has been very re-
producible and readily elicited by IgG isolated from four of
four rabbits immunized with human keratinocyte-derived
laminin 5. These results imply that the immunodominant por-
tion of this protein plays a key role in maintaining adhesion of
basal keratinocytes to epidermal BM in vivo. While rabbits im-
munized with laminin 5 developed high titers of IgG directed
against human and murine epidermal BMs, these subjects had
no in situ deposits of IgG in their epidermal BMs, and their
sera showed no reactivity to epidermal BMs in multiple sam-
ples of normal rabbit skin. Moreover, upon breeding, two im-
mune females produced litters of normal pups despite the sus-
tained presence of high-titer anti–laminin 5 IgG that was
passaged transplacentally to the circulation (but not to the in-
tact epidermal BMs) of their newborns. While the exact expla-
nation for this observation is unknown, it is suspected that the
rabbits deleted their clones of autoreactive lymphocytes.
These studies establish the first animal model of the human
blistering disease cicatricial pemphigoid and create an experi-
mental system that can be used to investigate disease patho-
mechanisms and experimental therapies. This model can also
be used to assess the pathogenic activity of antibodies raised
against specific subunits of laminin 5, as well as portions of
these subunits that are recognized to possess important bio-
logic activities. Similarly, when mapping studies have defined
the epitopes within laminin 5 that are targeted by circulating
autoantibodies from patients with cicatricial pemphigoid, it
should be possible to use this model to determine if such immu-
nodominant sites harbor pathogenic epitopes as well. This ap-
proach should also further elucidate the mechanism whereby
laminin 5 promotes the adhesion of epidermis to epidermal
BM in vivo.
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